These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17211375)

  • 1. Genentech makes its first-ever acquisition.
    Hollmer M
    Nat Biotechnol; 2007 Jan; 25(1):4-5. PubMed ID: 17211375
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiinfective biotechs face partnering gap.
    Sheridan C
    Nat Biotechnol; 2005 Feb; 23(2):155-6. PubMed ID: 15696131
    [No Abstract]   [Full Text] [Related]  

  • 3. Earlier stage biotechs attract partners.
    Ratner M
    Nat Biotechnol; 2005 May; 23(5):509. PubMed ID: 15877052
    [No Abstract]   [Full Text] [Related]  

  • 4. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 5. Never again.
    Scott C
    Nat Biotechnol; 2010 Feb; 28(2):131. PubMed ID: 20139946
    [No Abstract]   [Full Text] [Related]  

  • 6. A very firm handshake: biotech's growing negotiating power.
    Thiel KA
    Nat Biotechnol; 2005 Oct; 23(10):1221-6. PubMed ID: 16211058
    [No Abstract]   [Full Text] [Related]  

  • 7. Sugen falls as casualty of Pfizer-Pharmacia merger.
    Garber K
    Nat Biotechnol; 2003 Jul; 21(7):722-3. PubMed ID: 12833079
    [No Abstract]   [Full Text] [Related]  

  • 8. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 9. Exiting this year and into the next.
    Nat Biotechnol; 2005 Dec; 23(12):1451. PubMed ID: 16333272
    [No Abstract]   [Full Text] [Related]  

  • 10. The closure of Sugen.
    Levitzki A
    Nat Biotechnol; 2003 Sep; 21(9):969. PubMed ID: 12949548
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 12. Selling out.
    Martin JF
    Nat Biotechnol; 2010 Apr; 28(4):315-7. PubMed ID: 20383912
    [No Abstract]   [Full Text] [Related]  

  • 13. Anthony Coyle.
    Coyle A
    Nat Biotechnol; 2011 Mar; 29(3):187. PubMed ID: 21390006
    [No Abstract]   [Full Text] [Related]  

  • 14. Michigan's next wave of biopharmaceutical entrepreneurship.
    Kerppola R; van de Walle M; Surine S
    Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
    [No Abstract]   [Full Text] [Related]  

  • 15. Elias Zerhouni.
    Zerhouni E
    Nat Biotechnol; 2011 Mar; 29(3):188. PubMed ID: 21390007
    [No Abstract]   [Full Text] [Related]  

  • 16. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

  • 17. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 18. Filters for preparing to meet a venture capitalist.
    Christoffersen R
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE49-50. PubMed ID: 12874981
    [No Abstract]   [Full Text] [Related]  

  • 19. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 20. Swedish roadtrip.
    Herrera S
    Nat Biotechnol; 2006 Jan; 24(1):15. PubMed ID: 16475247
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.